Investigation of the anti-complement agents, FUT-175 and K76COOH, in discordant xenotransplantation

Xenotransplantation

Volumn 3, Issue 3, 1996, Pages 237-245

  Kobayashi, T ^a,b   Neethling, F A ^a   Taniguchi, S ^a   Ye, Y ^a   Niekrasz, M ^c   Koren, E ^d   Hancock, W W ^e   Takagi, H ^b   Cooper, D K C ^a,f  

^a INTEGRIS Nazih Zuhdi Transplant Institute   (United States)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti complement agents; FUT 175; Hyperacute rejection; K76COOH

Indexed keywords

EID: 0000206613     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3089.1996.tb00143.x     Document Type: Article

References (27)

1. PAUL LC. Mechanism of humoral xenograft rejection. In: Cooper DKC., Kemp E, Reemtsma K, White DJG, eds. Xenotransplantation. Heidelberg: Springer, 1991, pp. 47-67.
2. PLATT JL, FISCHEL RJ, MATAS AJ, REIF SA, BOLMAN RM, BACH FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52:214-220.
3. COOPER DKC, KOREN E, ORIOL R. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994; 141: 31-58.
4. LEVENTHAL JR, SAKIYALAK P, WITSON J, et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 1994; 57:974-978.
5. MIYAGAWA S, SHIRAKURA R, MATSUMIYA G, et al. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation 1993; 55:709-713.
6. STARZL TE, TZAKIS A, FUNG JJ, et al. Prospects of clinical xenotransplantation. Transplant Proc 1994; 26:1082-1088.
7. KAWAUCHI M, TAKEDA M, NAKAJIMA J, MATSUMOTO J, FURUSE A. Cardiac xenotransplantation from pig to Japanese monkey with splenectomy, tacrolimus, filtration plasmapheresis and nafamstat mesilate. Transplant Proc 1994; 26:1076-1077.
8. OHTA K, TANAKA N, ORITA K. Discordant liver xenograft transplantation. Transplant Proc 1994; 26:2435-2438.
9. AOYAMA T, INO Y, OZEKI M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. 1. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984; 35:203-227.
10. ISSEKUTZ AC, ROLAND DM, PATRICK RA. The effect of FUT-175 (nafamstat mesilate) on C3a, C4a and C5a generation in vitro and inflammatory reactions in vivo. Int J Immunopharmacol 1990; 12:1-9.
11. KATO H, INOUE M, YAMAMURA Y, et al. Mechanism of polymorphonuclear leukocytes accumulation examined using inhibitors of complement and arachidonic acid cascade in rats treated with OK-432. Nat Immun Cell Growth Reg 1989; 8:290-300.
12. 2) and hydroxyl radical production by human polymorphonuclear leukocytes. Hepato-Gastroenterol 1992; 39:59-61.
13. HITOMI Y, IKARI N, FUJII S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985; 15:164-168.
14. 2 and thrombin inhibitors or fibrinolytic agent on platelet aggregation and disaggregation. Rinsho Ketsueki Jpn J Clin Hematol 1984; 25:998-1003.
15. POE M, WU JK, BLAKE JT, SWEERINK HJ, SIGAL NH. The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic, antiprotease, FUT-175. Arch Biochem Biophys 1991; 284:215-218.
16. HONG K, KINOSHITA T, MIYAZAKI W, IZAWA T, INOUE K. An anticomplementary agent, K76 monocarboxylic acid: Its site and mechanism of inhibition of the complement activation cascade. J Immunol 1979; 122:2418-2423.
17. KONNO S, TSURUFUJI S. Induction of zymosan-air-pouch inflammation in rats and its characterization with reference to the effects of anticomplementary and anti-inflammatory agents. Br J Pharmacol 1983; 80:269-177.
18. HUDIG D, REDELMAN D, MINNING L, CARINE K. Inhibition of human lymphocyte natural cytotoxicity and antibody-dependent cell-mediated cytotoxicity by K-76 COONa, a reagent that blocks complement activity. J Immunol 1984; 133:408-414.
19. TOKI J, MIYAZAKI W, INABA M, et al. Effects of K-76COOH (MX-1) on immune response: induction of suppressor T-cells by MX-1. Int J Immunopharmacol 1992; 14:1093-1098.
20. KOREN E, NEETHLING FA, RICHARDS S, et al. Binding and specificity of major immunoglobulin classes of preformed human anti-pig heart antibodies. Transplant Int 1993; 6:351-353.
21. KOREN E, NEETHLING FA, KOSCEC M, et al. In vitro model for hyperacute rejection of xenogeneic cells. Transplant Proc 1994; 26:1166.
22. MANN F.C, PRIESTLEY JT, MARKOWITZ J, YATER WM. Transplantation of the intact mammalian heart. Arch Surg 1933; 26:219-224.
23. TAKAHASHI H, TAKIZAWA S, TATEWAKI T, et al. Nafamstat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulation. Thromb Haemost 1989; 62:372.
24. TANAKA M, MURASE N, MIYAZAWA H, et al. Effect of anti-complement agent K-76COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. Transplant Proc 1995; 27:275-276.
25. KOBAYASHI T, TANIGUCHI S, YE Y, et al. Delayed xenograft rejection in C3-depleted discordant (pig-to-baboon) cardiac xenografts treated with cobra venom factor. Transplant Proc 1996; 28:560.
26. SHIBUYA M, SASAKI H, KUROTORI M, et al. Pharmokinetic studies of FUT-175 (nafamstat mesilate) (4): Metabolism in rats and dogs. Kiso To Rinsho (in Japanese) 1984; 18:4023-4035.
27. AOYAMA T. Nafamstat mesilate. Drugs Future 1984; 9:747-748.